Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TMDX
SellFallen FavouriteTransMedics Group, Inc. · Healthcare · United States · $3.1B · Avg Vol: $72M/d
28
StockRankGet insider-trade alerts
Q
69
V
33
M
14
P/E (TTM)
23.3x
ROE
36.3%
D/E
1.7x
Dividend %
—
COMPANY DESCRIPTION
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 93.5M | 241.6M | 441.5M | 605.5M | 86.4% | 668.5M | 741.7M | 874.7M | 20.2% |
| EPS | -1.23 | -0.77 | 1.07 | 5.60 | 423.4% | 3.86 | 3.32 | 4.91 | -6.3% |
| Shares | 32.1M | 32.7M | 33.6M | 34.3M | +6.6% | 34.7M | — | — | — |
| Debt | 67.6M | 515.9M | 518.3M | 519.3M | 97.4% | 867.7M | — | — | — |
| Equity | 187.4M | 137.2M | 228.6M | 473.1M | 36.2% | — | — | — | — |
| Op CF | -45.8M | -13.0M | 48.8M | 192.8M | 295.1% | 145.9M | — | — | — |
| Inv CF | 54.5M | -194.0M | -129.3M | -59.3M | — | — | — | — | — |
| Fin CF | 167.9M | 400.4M | 22.9M | 16.9M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+11.1%
SMA 50SMA 200
Close
$86.62
RSI (14)
38.0
52W High
$156.00
From 52W High
0.6%
SCORE BREAKDOWN
Quality
69
ROIC
9.6%70.2
ROE
36.3%95.9
GP/Assets
36.7%73.8
Op. Margin
12.5%69.0
FCF/Assets
7.4%79.4
Piotroski
783.9
Int. Cover
4.4x50.2
D/E Ratio
1.67x7.0
Current Ratio
6.63x79.7
Value
33
P/E (TTM)
23.3x52.7
EV/EBITDA
30.4x20.7
P/FCF
38.8x36.8
P/B
6.0x22.8
P/S
4.7x43.4
Div Yield
—N/A
Momentum
14
52W High %
56%29.3
RS 6M
-47%14.5
SMA 50/200
0.78x13.5
EPS Rev 4W
-19.6%4.6
EPS Rev 12W
-35.1%3.6
EPS Improve
-40%10.9
Q Growth
-58%8.4
FUNDAMENTALS
Market Cap
$3.1B
P/E (Forward)
39.0x
Gross Margin
58.7%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TMDX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TMDX | TransMedics Group, Inc.(you) | $3.1B | 28 | Sell |
| IRTC | iRhythm Holdings, Inc. | $4.0B | 34 | Sell |
| ESTA | Establishment Labs Holdings Inc. | $2.1B | 23 | Sell |
| ALMR | Alamar Biosciences, Inc. | $2.1B | 20 | Sell |
| ATEC | Alphatec Holdings, Inc. | $1.5B | 27 | Sell |
| TNDM | Tandem Diabetes Care, Inc. | $1.5B | 31 | Sell |
| BFLY | Butterfly Network, Inc. | $2.2B | 41 | Hold |
| LMRI | Lumexa Imaging Holdings, Inc. | $1.1B | 28 | Sell |
| NEOG | Neogen Corporation | $2.5B | 46 | Hold |
| QDEL | QuidelOrtho Corporation | $1.0B | 29 | Sell |
Peer medians: ROE -30.8% · P/E 27.1x · Gross margin 58.1%